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Objectives: In light of increased risk of cardiovascular events and the poor prognosis of coronary artery disease (CAD) in diabetic versus non-
diabetic patients and also with respect to the importance of early diagnosis of CAD in this status, the study was aimed to assess the importance 
of microalbuminuria in predicting silent myocardial ischemia (SMI) in patients with type 2 diabetes using myocardial perfusion imaging (MPI).
Methods: This study included 120 patients with diabetes type 2, but without previously known CAD or any cardiac symptoms that were stratified 
into two groups based on presence/absence of microalbuminuria. All participants underwent CAD evaluation using gated myocardial perfusion 
single-photon emission computed tomography (MPS) imaging. Other clinical and laboratory indices were also recorded.
Results: Studied population consisted of 84 males (70%) and 36 females (30%), totally 120 patients with mean age of 58.61±9.90). In total, 
asymptomatic ischemia was detected in 78 (65%) of the included diabetic patients. Stress induced ischemia was found in 56 patients (87.5%) 
of albumin+ (Alb) group and in 22 patients (39.3%) of Alb- group. The frequency of stress induced ischemia was 10.81 times higher in the 
patients with microalbuminuria compared to Alb- ones [p<0.001, Odds ratio: 10.81, 95% confidence interval: 4.33-26.99]. On the other hand, 
no relationship was found between the presence of stress induced ischemia and therapy type, diabetes duration, history of evident retinopathy, 
history of hypertension and also serum levels of hemoglobin A1c (p>0.05).
Conclusion: The current study showed that abnormal MPI findings are significantly more common in diabetic patients with microalbuminuria. 
With respect to low cost and availability of urine Alb detection tests, it might be as a biomarker for prediction of SMI in diabetic population.
Keywords: Microalbuminuria, silent myocardial ischemia, type 2 diabetes, myocardial perfusion imaging 
Abstract
Amaç: Bu çalışmada diyabetik olgularda diyabetik olmayanlara göre kardiyovasküler olay riskinin yüksek ve koroner arter hastalığı (CAD) 
prognozunun kötü olmasından yola çıkarak tip 2 diyabette CAD’nin erken tanısında mikroalbuminürinin önemi miyokard perfüzyon sintigrafisinde 
(MPS) saptanan sessiz miyokard iskemisi (SMİ) bulguları ile birlikte değerlendirilmektedir. 
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Introduction
Type 2 diabetes is defined as impairment of the ability to 
produce or respond to the insulin hormone, leading to 
abnormal metabolism of carbohydrates and increasing in 
levels of blood glucose. The risk of type 2 diabetes increases 
with age specifically over 50 years old.
Globally about 400 million adults are living with diabetes 
mellitus around the world and it is predicted that this 
number will be increased to more than 640 million until 
year 2040 (1).
About 4 million deaths per year are attributable to diabetes 
side effects, which is 9% of all deaths worldwide. These 
side effects include cardiovascular and cerebrovascular 
attacks, retinopathy, nephropathy, neuropathy and non-
traumatic limbs amputations (2,3,4,5). 
Cardiovascular events including coronary artery disease 
(CAD) 40% and other cardiac disorders like chronic 
heart failure 15% are the leading cause of morbidity and 
mortality of patients with diabetes, and death will occur 
14.6 years earlier in type 2 diabetic patients compared to 
non-diabetics (5).
Microalbuminuria, defined as urinary albumin excretion of 
20-200 mg/day, is a marker of systemic vascular damage, 
renal functional impairment and CAD (2).The prevalence of 
microalbuminuria is estimated 19% in diabetic patients as a 
marker of renal, cardiac and cerebral vascular damage (6).
 Clinically patients with diabetes are more likely to be 
without chest pain in the setting of unstable angina, 
myocardial infarction or during exercise testing, and thus 
late presentation contributes to late CAD diagnosis and a 
higher mortality in these patients (7).
Silent myocardial ischemia (SMI) is classically described 
as an objective document of myocardial ischemia in 
patients without subjective ischemia symptoms. Now, 
there are different clinical methods in the diagnostic 
evaluation of CAD. Coronary artery angiography (CAG) 
is the gold standard for distinguishing of asymptomatic 
CAD. Computed tomography coronary angiography 
(CTCA) can depict anatomy, trend and extent of coronary 
stenosis. Myocardial perfusion imaging (MPI) uses to 
diagnose whether anatomical stenosis yields to myocardial 
dysfunction, to assess the risk estimation and prognosis of 
myocardial disease and also is frequently applied in clinical 
evaluation of CAD (8,9,10,11,12,13). 
In view of increased risk of cardiovascular events and the 
poor prognosis of CAD in diabetic versus non-diabetic 
patients and also with respect to the importance of early 
diagnosis of CAD in this status, the study was aimed to 
assess the importance of microalbuminuria in predicting 
SMI in patients with type 2 diabetes using MPI.
Material and Methods
Study Population
Our study was designed as a non-randomized cross 
sectional clinical study. The study evaluated 120 patients 
with known and established diabetes type 2, but without 
previously known CAD or any cardiac symptoms.
The patients with past history of acute coronary syndrome, 
myocardial ischemia, abnormal electrocardiogram, previous 
myocardial infarction, percutaneous CTCA, coronary 
artery bypass graft surgery, peripheral vascular disease, 
established predisposing malignancy, chronic inflammatory 
disorders (vasculitis, rheumatoid arthritis, systemic lupus 
erythematosus), severe systemic illnesses and renal diseases 
were excluded from the study. 
Evaluation for CAD was performed using MPI gated single-
photon emission computed tomography (SPECT) imaging 
in the department of nuclear medicine of a university 
affiliated hospital. MPI findings were compared to the 
microalbuminuria status. Other clinical indices like presence 
of retinopathy, hypertension, systolic and diastolic blood 
pressure, liver function tests (aspartate aminotransferase, 
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Yöntem: Önceden bilinen CAD ve kardiyak semptomu bulunmayan tip 2 diyabetli 120 olgu çalışmaya dahil edilerek mikroalbuminüri varlığına/
yokluğuna göre iki gruba ayrılarak incelendi. Tüm hastalara CAD’yi değerlendirmek üzere miyokard perfüzyon tek-foton emisyonlu bilgisayarlı 
tomografi ile görüntüleme yapıldı. Ayrıca diğer klinik ve laboratuvar verileri toplandı.
Bulgular: Çalışma grubu 84 erkek (%70) ve 36 kadından (%30) oluşan, yaş ortalaması 58,61±9,90 olan 120 hastalık bir gruptur. Gruba dahil edilen 
diyabetik olguların 78’inde (%65) asemptomatik iskemi saptandı. Albumin+ (Alb) olguların 56’sında (%87,5), Alb- olguların 22’sinde (%39,3) stres 
iskemisi bulundu. Mikroalbuminüri bulunan olgularda stres iskemisi sıklığı diğerlerine göre 10,81 kez fazlaydı [p<0,001, Odds oranı: 10,81, %95 
güven aralığı: 4,33-26,99]. Öte yandan, stres iskemisi ile tedavi tipi, diyabetin süresi, bariz retinopati öyküsü, hipertansiyon ve serum hemoglobin 
A1c düzeyi arasında ilişki bulunmadı (p>0,05).
Sonuç: Bu çalışma mikroalbuminürisi bulunan diyabetik olgularda MPS’sinde anormal bulguların daha sık olduğunu göstermektedir. Düşük maliyeti 
ve kolay temini nedeniyle idrarda albumin ölçümü diyabetik popülasyonda SMİ’yi öngörmede bir biyobelirteç olarak kullanılabilir. 
Anahtar kelimeler: Mikroalbuminüri, sessiz miyokard iskemisi, tip 2 diyabet, miyokard perfüzyon sintigrafisi
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alanine aminotransferase, alkaline phosphatase), serum 
lipid profile (high density lipoprotein, low density 
lipoprotein, thyroglobulin), hemoglobin A1c (HbA1c) and 
blood urea nitrogen/serum creatinine were also recorded. 
It should be mentioned that all eligible patients signed an 
inform consent. This study complies with the Declaration 
of Helsinki, and it was approved by the Institutional Ethics 
Committee of Bushehr University of Medical Sciences. 
Microalbuminuria Assessment: Microalbuminuria was 
measured after 24 h urine collection and the patients 
were divided into two groups with microalbuminuria [renal 
albumin excretion between 20-200 mg/day, albumin+ (Alb)] 
and without microalbuminuria (renal albumin excretion less 
than 20 mg/day, Alb-). The patients with more than 200 
mg/day were excluded. 
Gated-SPECT MPI: Patients were instructed to refrain 
from caffeine-containing beverages for at least 12 hours, 
nitrates for 24 hours and beta-blockers for 48 hours before 
the study. 
A two-day stress/rest MPI protocol was carried out for all 
patients. At stress phase, weight –adjusted doses of 10 
MBq/kg of Tc-99m methoxyisobutylisonitrile (at least 700 
MBq) was injected at peak pharmacologic stress and the 
similar dose was injected at rest for each patient on the 
next day.
Pharmacologic stress was obtained by 0.56 mg/kg of 
body weight of dipyridamole in 20 mLnormal saline 
which was injected intravenously during 5 minutes under 
electrocardiographic monitoring. Four minutes later, Tc-99m 
MIBI was injected.
SPECT acquisition was performed almost 30 minutes later. 
At the rest phase, almost 45 minutes after injection of 
Tc-99m MIBI, SPECT acquisition was performed for each 
patient. 
SPECT Imaging Protocol: Images were done over a 180º 
orbit from right anterior oblique 45º to left posterior oblique 
45º using a dual-head γ-camera (ADAC, USA) equipped with 
ultra-high resolution collimator. Acquisition was carried out 
in 32 steps at 30 seconds per stepusing the step- acquisition 
mode. For image acquisition, a 20% acceptance window 
around the 140 keV photopeak was applied. A 64x64 
matrix was applied for all acquisitions. The prefilteration of 
projection datasets was performed by a Butterworth filter 
and images were reconstructed by filtered back-projection. 
For all images, a technologist experienced in nuclear 
cardiology reconstructed the raw data.
Interpretation of MPIs: All images were assessed 
qualitatively by two experienced  practitioners,  who 
reached an agreement on the results. The physicians were 
blind to the patient’s data. Segmental perfusion defect in 
the stress phase images, which revealed filling-in (more 
uptake) in the rest phase study was considered as ischemia 
or reversible perfusion defect. Segment with perfusion 
defect in the stress phase scan with no alteration in size 
or amount of uptake (perfusion score) in the rest phase 
images were considered as irreversible perfusion defect or 
scar tissue.
Statistical Analysis
The continuous variables are presented as the mean 
± standard deviation, and categorical variables as the 
absolute values and percentages. Categorical variables 
were compared using chi-square test and continuous 
variables using unpaired Student’s t-test. Statistical analysis 
was performed with the use of the SPSS Statistical Package 
(version 20). A p value <0.05 was considered statistically 
significant.
Results
Studied population consisted of 84 males (70%) and 36 
females (30%), totally 120 patients with mean age of 
58.61±9.90 years old. In terms of duration of diabetes, 
39 patients (32.5%) had more than 10 years, 39 patients 
(32.5%) had between 5-10 years and 42 patients (35%) 
had less than five years diabetes history. Anti-diabetic 
therapy used by the patients were as follow: 44 patients 
(36.7%) metformin, 33 patients (27.5%) metformin 
and glibenclamide combination, seven patients (5.8%) 
glibenclamide, six patients (5%) metformin and insulin 
combination, three patients (2.5%) insulin and one patient 
(0.8%) metformin, glibenclamide and insulin combination 
(Table 1). In addition, 87 patients were using aspirin. The 
type of antidiabetic therapy in our participants, did not show 
any significance in neither group Alb+ nor Alb- (p>0.05).
Totally, 64 patients (53.3%) had the history of 
microalbuminuria, 30 patients (25%) had the history of 
established retinopathy and 76 patients (63.3%) had the 
history of hypertension.
Comparison of Diabetic Patients with and without 
Microalbuminuria: From 64 patients with established 
microalbuminuria (group Alb+), 25 (39.1%) were male and 
Table 1. Patient’s data according to the use of antidiabetic 
medication 
Therapy type Group Alb+ Group Alb- p value
Insulin 8 (12.5%) 2 (3.6%) 0.07
Sulfonylureas 20 (31.3%) 21 (37.5%) 0.47
Metformin 45 (70.3%) 39 (69.6%) 0.93
Aspirin 47 (73.4%) 40 (71.4%) 0.80
Alb: Albumin
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39 (60.9%) were female, and from 56 patients without 
evident microalbuminuria (group Alb-), 11 (19.6%) and 45 
(80.4%) were male and female respectively. The abundance 
of microalbuminuria incidence was 2.62 times higher in 
males compared to female patients [Odds ratio (OR): 2.62, 
95% confidence interval (CI): 1.14-6.00, p=0.02].
Average age of the patients with and without 
microalbuminuria was 59.37±9.42 years old and 
57.75±10.43 years old, respectively which showed no 
statistical significance (p=0.37).
From 64 patients in group Alb+, 41 (64.1%) and 23 (35.9%) 
cases had evident diabetes more and less than five years, 
respectively. Likewise, from 56 patients in group Alb-, 25 
(44.6%) and 31 (55.4%) cases had evident diabetes more 
and less than five years, respectively.
Among all diabetic patients in our study, the risk of 
developing microalbuminuria was 2.21 times higher in 
patients with the history of over five years diabetes disease 
compared to the patients with the history of less than 
five years evident diabetes (OR: 2.21, 95% CI: 1.06-4.60, 
p=0.03).
The average of the duration of diagnosed diabetes were 
9.21±6.56 years in group Alb+ and 6.66±4.84 years in 
group Alb- and showed statistically significance (p=0.01).
Among the patients with microalbuminuria, 20 (31.3%) 
and among the patients without microalbuminuria, 10 
(17.9%) had the history of retinal vascular surgery but it 
didn’t show statistically significance (p=0.09).
Likewise, in group Alb+, 41(64.1%) patients and in group 
Alb-, 35 (62.5%) patients had the history of diagnosed 
hypertension (p=0.85).
The average of systolic and diastolic blood pressures was 
126.17±4.77 mmHg and 84.68±4.16 mmHg, as well as in 
group Alb+, 125.98±4.90 mmHg and 84.10±4.27 mmHg in 
group Alb- (p=0.83, p=0.45), respectively.
Laboratory test results are shown in Table 2 and showed no 
significance between group Alb+ and Alb- (p>0.05).
Myocardial Gated SPECT Findings: In total, SMI was 
detected in 78 (65%) of the included diabetic patients. 
Stress induced ischemia was found in 56 patients (87.5%) 
of Alb+ group and in 22 patients (39.3%) of Alb- group. As 
described, the frequency of stress induced ischemia was 
10.81 times higher in the patients with microalbuminuria 
compared to Alb- patients (p<0.001, OR: 10.81, 95% 
CI: 4.33-26.99). Likewise, this ischemic status was also 
correlated to the gender and occurred 2.95 times more 
in males than females. From 36 male cases, 29 (80.55%) 
and from 84 female cases, only 49 (58.33%) showed 
stress induced myocardial ischemia (OR: 2.95, 95% CI: 
1.16-7.51, p=0.019). No correlation was found among 
the presence of stress induced ischemia and therapy type, 
diabetes duration, history of evident retinopathy, history 
of hypertension and serum levels of HbA1c (p>0.05). In 
addition, cardiac SPECT findings revealed presence of septal 
hypertrophy in 40 patients (62.5%) of group Alb+ and in 
37 patients (66.1%) of group Alb- without any statistically 
significance (p=0.684).
Average ejection fraction (FE) was estimated 53.51±3.17% 
for Alb+ patients and 56.07±3.77% for Alb- ones and EF 
was significantly higher in Alb- patients compared to the 
other group (p=0.001) (Table 3). 
Discussion 
Diabetes mellitus is one of the major disabling diseases 
around the world. Prevalence and incidence of type 
2 diabetes is increasing over time especially in under 
developed countries. Increasing diabetes prevalence will 
lead to increasing the side effects of this disease as well as 
patient’s morbidity and mortality. Diabetes is accompanied 
with 2 to 4 times increased risk of the CAD development 
and progression (14). The mortality resulted from any 
Table 2. The presentation of overall laboratory tests
Laboratory results Group Alb+ Group Alb- p value
TG (mg/dL) 191.23±23.96 192.58±20.57 0.74
LDL (mg/dL) 86.03±7.18 86.17±7.29 0.91
HDL (mg/dL) 31.89±4.58 32.64±4.22 0.35
HbA1c (average):
<7%
≥7%
7.01±0.54 7.16±0.56 0.14
37 (57.8%) 36 (64.3%) 0.46
27 (42.2%) 20 (35.7%)
BUN (mg/dL) 16.92±8.73 15.63±8.61 0.41
SCr (mg/dL) 1.05±0.63 0.87±0.41 0.07
AST (U/L) 23.67±6.52 23.17±6.72 0.68
ALT (U/L) 26.42±9.56 24.26±7.40 0.17
ALP (U/L) 168.23±32.77 172.46±28.55 0.45
Alb: Albumin, TG: Thyroglobulin, BUN: Blood urea nitrogen, SCr: Serum creatinine, 
LDL: Low density lipoprotein, HDL: High density lipoprotein, HbA1c: Hemoglobin 
A1c, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline 
phosphatase
Table 3. Myocardial perfusion single-photon emission 
computed tomography findings
MPI findings Group Alb+ Group Alb- p value
Septal hypertrophy 40 (62.5%) 37 (66.1%) 0.68
Ejection fraction 53.51±3.17% 56.07±3.77% <0.00
Ischemia (+) 56 (87.5%) 22 (39.3%) <0.00
Ischemia (-) 8 (12.5%) 34 (60.7%)
Alb: Albumin, MPI: Myocardial perfusion imaging
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cause including CAD likely will be more in younger patients 
who have also higher serum glucose levels and suffer from 
diabetic nephropathy (15,16).
SMI is the most common manifestation of CAD in diabetic 
patients and can be manifested as myocardial infarction or 
death in some patients. The reported prevalence of SMI 
in diabetic patients ranges between 6 to 57% (17,18), 
but it was estimated 65% in our recent study which could 
be related to the use of different methodologies through 
the studies. Diabetic neuropathy is the most common 
underlying cause of silent ischemia in about 22-42% of 
asymptomatic diabetic patients (19,20,21). Furthermore, 
about 19% of diabetics have renal protein excretion and 
most studies found the increased risk of cardiovascular 
events in the patients with overt microalbuminuria (22,23). 
Microalbuminuria is the first sign of renal involvement 
and incoming diabetic nephropathy (10), likewise it 
could be taken as an accurate and sensitive predictive 
indicator of end stage renal disease in diabetic patients (6). 
Microalbuminuria is also a marker of cardiac and cerebral 
vascular damage in addition to renal damage (2).
Accordingly, this study was designed to show the 
correlation between microalbuminuria and the presence 
of CAD in asymptomatic diabetic patients by evaluation 
of myocardial perfusion scan findings. Our study showed 
that, although the duration of diabetes is not correlated 
to patient’s gender, the frequency of the development of 
microalbuminuria is 2.62 times higher in males. Probability 
of microalbuminuria development in diabetic patients was 
2.21 times higher in patients with the history of diabetic 
disease more than five years.
In the evaluation of MPI findings, average FE was lower 
in patients with microalbuminuria and also prevalence of 
ischemia was 10.81 times higher than the patients without 
microalbuminuria. This result is contrary to the results 
of The Detection of Ischemia in Asymptomatic Diabetics 
(DIAD) study by Wackers et al. (18), which showed no 
significant association between microalbuminuria and 
perfusion defects on myocardial perfusion scan.
Ischemia was also correlated with patient’s gender and 
we found ischemia 2.95 times more in males than females 
as in DIAD study by Wackers et al. (18). We also found 
no association between myocardial ischemia and therapy 
type, diabetes duration, history of retinopathy, history of 
hypertension and serum levels of HbA1c.
Salehi et al. (11) evaluated the MPI findings in diabetic 
patients, and they found a relationship between diabetes 
duration and abnormal MPI findings, so that patients with 
longer diabetes duration showed 2.27 times more MPI 
abnormalities. These results were contrary to our findings. 
They indicated that performing myocardial perfusion SPECT 
in asymptomatic diabetic patients will lead to early CAD 
diagnosis and should be considered as a screening tool in 
cases with diabetes.
Shmendi et al. (24) evaluated the findings of myocardial 
perfusion scan in diabetic patients with a suspicion of 
myocardial ischemia. They found that abnormal MPI findings, 
including stress inducible ischemia, were seen more in 
diabetic patients compared to non-diabetics. On the other 
hand, HbA1c >7% was related to more abnormal myocardial 
perfusion SPECT (MPS) findings and ischemia risk in diabetic 
patients. The results of this study are not in agreement 
with our current results as we did not find any correlation 
between myocardial ischemia and HbA1c level >7%. Finally, 
they showed that the frequency of abnormal MPS findings 
and myocardial ischemia is higher in diabetic patients versus 
non-diabetics. Likewise poorer control of serum glucose level 
resulted more probability of ischemia in diabetics.
In another study, Al-Humaidi et al. (10) worked on 
myocardial perfusion scan abnormalities in asymptomatic 
patients with type 2 diabetes. They found abnormal 
MPI findings in 22 (37%) of 59 patients. In their study, 
abnormal MPI was found to be correlated well with 
diabetes duration, insulin therapy, diabetic nephropathy 
and neuropathy. However in the current study, only gender 
and microalbuminuria were correlated with abnormal MPS 
results. They also represent that abnormal MPI results are 
more prevalent in asymptomatic diabetic patients and they 
should be screened with MPI if they have high CAD pre-test 
probability.
Potier et al. (14) assessed the correlation between cardiac 
microvascular dysfunction and microalbuminuria in diabetics 
with 82Rubidium-positron-emission tomography scan. In their 
study, myocardial flow reserve (MFR) was significantly lower 
in diabetic patients versus non-diabetics. On the other hand, 
MFR was progressively declined parallel to increasing albumin 
secretion in urine. Whereas MFR as a marker of myocardial 
ischemia, the results of their study are consistent with our 
results. MFR was not significantly different in patients with 
or without retinopathy but micro and macroalbuminuria was 
associated with abnormal MFR. They finally emphasized that 
abnormal MFR is strongly related to diabetes and the severity 
of albumin secretion in urine.
In a study by Giovacchini et al. (25) the frequency of CAD 
in diabetic patients was evaluated and in similar to our 
study, their results showed that microalbuminuria is the 
only predicting factor for silent ischemia in asymptomatic 
diabetic patients and the incidence of ischemia is 4.42 
times higher in patients with microalbuminuria.
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Furthermore, it has been shown that microalbuminuria 
and left ventricular hypertrophy are both associated with 
increased cardiovascular morbidity and mortality, especially 
in diabetic patients. Therefore, it has been recommended 
that patients with type 2 diabetes and increased urinary 
albumin excretion should be check for increased left 
ventricular mass as an important and potentially reversible 
cardiovascular risk factor (26,27,28). 
Additionally, it has been demonstrated that increased septal 
perfusion observed on MPI is the signal of asymmetrical 
septal hypertrophy which can be graded based on its 
severity (29). In our study, although the septal hypertrophy 
was shown in 76 patients, it was not statistically significant 
between two Alb+ and Alb- groups (p value >0.05). 
Study Limitations
It should also be mentioned that our study has some 
limitations. The most important limitation is the lack of 
follow-up to assess the patient’s clinical outcome; although 
in our prior experience, about 50% of the patients with 
abnormal MPI findings demonstrated abnormal CAG (13) 
and also should be considered the point that CAG does 
not reflect myocardial perfusion at the terminal coronary 
circulation and in cases with SMI, false negative findings 
may happen. The small sample size and lack of quantitative 
evaluation of myocardial ischemia on MPS are other 
limitations that should be underlined. Further well-designed 
studies with large number of patients using quantitative 
analysis of myocardial perfusion SPECT will be required to 
validate its clinical role.
Conclusion
The current study showed that abnormal MPI findings 
are significantly more common in diabetic patients with 
microalbuminuria. With respect to low cost and availability 
of urine albumin detection tests, it might be as a biomarker 
for prediction of SMI in diabetic population.
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